Back to Results

A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Primary Sclerosing Cholangitis (PSC)

Study category: Digestive Health

Is this Study for You?

Let's Get Started!

Description

DUR-928 (investigational drug)

Details
Age

Adult

Eligibility

Diagnosis of PSC

Phase

II - Research Studies that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Lisa Forman,  MD

Lisa Forman, MD

Study ID

Protocol Number: 18-0123

ClinicalTrials.gov: NCT03394781

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers